Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Fiche publication
Date publication
juin 2015
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F
Lien Pubmed
Résumé
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugate containing an anti-CD79B monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. We aimed to assess the safety and clinical activity of polatuzumab vedotin in relapsed or refractory B-cell NHL and chronic lymphocytic leukaemia (CLL).
Mots clés
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Murine-Derived, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, CD79 Antigens, biosynthesis, Drug Administration Schedule, Female, Humans, Immunoconjugates, administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Lymphoma, Non-Hodgkin, drug therapy, Male, Middle Aged, Prognosis, Rituximab
Référence
Lancet Oncol.. 2015 Jun;16(6):704-15